search
Back to results

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

Primary Purpose

Xeroderma Pigmentosum

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Afamelanotide
Sponsored by
Clinuvel Europe Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Xeroderma Pigmentosum

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patient with a molecular-genetically confirmed diagnosis of XP-C or XP-V;
  • Aged 18-75 years.

Exclusion Criteria:

  • Known allergy to afamelanotide or the polymer contained in the implant;
  • Presence of severe hepatic disease or hepatic impairment;
  • Renal impairment;
  • Any other medical condition which may interfere with the study protocol;
  • Existing melanoma;
  • Female who is pregnant or lactating;
  • Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures;
  • Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures;
  • Use of any other prior and concomitant therapy which may interfere with the objective of the study;
  • Participation in a clinical trial for an investigational agent.

Sites / Locations

  • CLINUVEL Investigational siteRecruiting
  • CLINUVEL Investigational siteRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Afamelanotide

Arm Description

Outcomes

Primary Outcome Measures

Change in minimal erythema dose (MED) in patients with XP-C.
MED is the lowest dose of UV light that causes reddening of the skin.
Change in MED in patients with XP-V.
MED is the lowest dose of UV light that causes reddening of the skin.

Secondary Outcome Measures

Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-C.
Analysis of UV photoproducts from skin samples.
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-C.
Analysis of DNA repair mechanisms from skin samples.
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-V.
Analysis of UV photoproducts from skin samples.
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-V.
Analysis of DNA repair mechanisms from skin samples.
Change in skin disease severity in patients with XP-C (A).
The higher the score, the more severe the disease.
Change in skin disease severity in patients with XP-V (A)
The higher the score, the more severe the disease.
Change in skin disease severity in patients with XP-C (B).
The higher the score, the more severe the disease.
Change in skin disease severity in patients with XP-V (B).
The higher the score, the more severe the disease.
Change in skin disease severity in patients with XP-C (C).
The higher the score, the more severe the disease.
Change in skin disease severity in patients with XP-V (C).
The higher the score, the more severe the disease.
Change in quality of life assessed by a disease specific tool (A) in patients with XP-C.
Higher scores represent worse health-related quality of life.
Change in quality of life assessed by a disease specific tool (A) in patients with XP-V.
Higher scores represent worse health-related quality of life.
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-C.
Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-V.
Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.

Full Information

First Posted
April 21, 2022
Last Updated
September 20, 2023
Sponsor
Clinuvel Europe Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05370235
Brief Title
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Official Title
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 28, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinuvel Europe Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Xeroderma Pigmentosum

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Afamelanotide
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Afamelanotide
Intervention Description
Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
Primary Outcome Measure Information:
Title
Change in minimal erythema dose (MED) in patients with XP-C.
Description
MED is the lowest dose of UV light that causes reddening of the skin.
Time Frame
From baseline to day 76.
Title
Change in MED in patients with XP-V.
Description
MED is the lowest dose of UV light that causes reddening of the skin.
Time Frame
From baseline to day 76.
Secondary Outcome Measure Information:
Title
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-C.
Description
Analysis of UV photoproducts from skin samples.
Time Frame
From baseline to day 76.
Title
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-C.
Description
Analysis of DNA repair mechanisms from skin samples.
Time Frame
From baseline to day 76.
Title
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-V.
Description
Analysis of UV photoproducts from skin samples.
Time Frame
From baseline to day 76.
Title
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-V.
Description
Analysis of DNA repair mechanisms from skin samples.
Time Frame
From baseline to day 76.
Title
Change in skin disease severity in patients with XP-C (A).
Description
The higher the score, the more severe the disease.
Time Frame
From baseline to day 76.
Title
Change in skin disease severity in patients with XP-V (A)
Description
The higher the score, the more severe the disease.
Time Frame
From baseline to day 76.
Title
Change in skin disease severity in patients with XP-C (B).
Description
The higher the score, the more severe the disease.
Time Frame
From baseline to day 76.
Title
Change in skin disease severity in patients with XP-V (B).
Description
The higher the score, the more severe the disease.
Time Frame
From baseline to day 76.
Title
Change in skin disease severity in patients with XP-C (C).
Description
The higher the score, the more severe the disease.
Time Frame
From baseline to day 76.
Title
Change in skin disease severity in patients with XP-V (C).
Description
The higher the score, the more severe the disease.
Time Frame
From baseline to day 76.
Title
Change in quality of life assessed by a disease specific tool (A) in patients with XP-C.
Description
Higher scores represent worse health-related quality of life.
Time Frame
From baseline to day 76.
Title
Change in quality of life assessed by a disease specific tool (A) in patients with XP-V.
Description
Higher scores represent worse health-related quality of life.
Time Frame
From baseline to day 76.
Title
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-C.
Description
Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.
Time Frame
From baseline to day 76.
Title
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-V.
Description
Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.
Time Frame
From baseline to day 76.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient with a molecular-genetically confirmed diagnosis of XP-C or XP-V; Aged 18-75 years. Exclusion Criteria: Known allergy to afamelanotide or the polymer contained in the implant; Presence of severe hepatic disease or hepatic impairment; Renal impairment; Any other medical condition which may interfere with the study protocol; Existing melanoma; Female who is pregnant or lactating; Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures; Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures; Use of any other prior and concomitant therapy which may interfere with the objective of the study; Participation in a clinical trial for an investigational agent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Head of Clinical Operations
Phone
+441372860765
Email
mail@clinuvel.com
Facility Information:
Facility Name
CLINUVEL Investigational site
City
Clinuvel Investigational Site
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Head of Clinical Operations
Phone
+441372860765
Email
mail@clinuvel.com
Facility Name
CLINUVEL Investigational site
City
Clinuvel Investigational Site
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Head of Clinical Operations
Phone
+441372860765
Email
mail@clinuvel.com

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

We'll reach out to this number within 24 hrs